Evidence for dissolution rate-limited absorption of COL-3, a matrix metalloproteinase inhibitor, leading to the irregular absorption profile in rats after oral administration

Pharmaceutical Research

Volumn 19, Issue 11, 2002, Pages 1655-1662

  Li, J ^a   Huynh, H ^b   Chan, E ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

COL 3; Dissolution rate limited absorption; Double or plateau peak phenomenon; Flip flop situation; Irregular absorption; Matrix metalloproteinase inhibitor

Indexed keywords

4 DEDIMETHYLAMINOSANCYCLINE; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; DISSOLUTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG ELIMINATION; ENTEROHEPATIC CIRCULATION; FOOD DRUG INTERACTION; GASTROINTESTINAL ABSORPTION; MALE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; STOMACH EMPTYING; SUSPENSION;

ADMINISTRATION, ORAL; ANIMALS; INTESTINAL ABSORPTION; MALE; MATRIX METALLOPROTEINASES; PROTEASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TETRACYCLINES;

EID: 0036844752     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1020901328583     Document Type: Article

References (36)

1. H. M. Lee, L. M. Golub, and C. Cao. CMT-3, a non-antimicrobial tetracycline (TC), inhibits MT1-MMP activity: relevance to cancer. J. Dent. Res. 77(IADR Abs.):926 (1998).
2. B. L. Lokeshwar. MMP inhibition in prostate cancer. Ann. N.Y. Acad. Sci. 878:271-289 (1999).
3. L. A. Liotta and W. G. Stetler-Stevenson. Metalloproteinase and cancer invasion. Sem. Cancer. Biol. 1:99-106 (1990).
4. W. G Stetler-Stevenson. S. Aznavoorian, and L. A. Liotta. Tumor cell interactions with the extracellular-matrix during invasion and metastasis. Ann. Rev. Cell. Biol. 9:541-573 (1993).
5. M. G. Selzer, B. Zhu, N. L. Block, and B. L. Lokeshwar. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paralegia in a rat model of prostate cancer. Ann. N.Y. Acad. Sci. 878:678-82 (1999).
6. R. E. Seftor, E. A. Seftor, and J. E. Delarco. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin. Exp. Metastasis. 16:217-225 (1998).
7. M. A. Rudek, W. D. Figg, and V. Dyer. W Dahut, M, L. Turner, S. M. Steinberg, D. J. Liewehr, D. R. Kohler, J. M. Pluda, and E. Reed. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol. 19:584-592 (2001).
8. J. T. Bettany and R. G. Wolowacz. Tetracycline derivatives induce apoptosis selectively in cultured monocytes and macrophages but not in mesenchymal cells. Adv. Dent. Res. 12:136-143 (1998).
9. S. Pinsuwan and F. A. Alvarez-Nunez. E. S Tabibi, and S. H. Yalkowsky. Degradation kinetics of 4-dedimethylamino sancycline, a new anti-tumor agent, in aqueous solutions. Int. J. Pharm. 181:31-40 (1999).
10. R. L. Oberle and G. L. Amidon. The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon. J. Pharmacokinet. Biopharm. 15:529-544 (1987).
11. E. Lipka, I. D. Lee, P. Langguth, H. Spahn-Langguth, E. Mutschler, and G. L. Amidon. Celiprolol double-peak occurrence and gastric motility: Nonlinear mixed effects modeling of bioavailability data obtained in dogs. J. Pharmacokinet. Biopharm. 23:267-286 (1995).
12. T. Ichikdawa, S. Ishida, Y. Sakiya, Y. Sawada, and M. Hanana. Biliary excretion and enterohepatic cycling of glycyrrhizin in rats. J. Pharm. Sci. 75:672-675 (1986).
13. J. Hasselstrom and J. Sawe. Morphine pharmacokinetics and metabolism in humans: Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin. Pharmacokinet. 24:344-354 (1986).
14. A. B. Suttle and K. L. B. Brouwer. Regional gastrointestinal absorption of ranitidine in the rat. Pharm. Res. 12:1311-1315 (1995).
15. A. B. Suttle, G. M. Pollack, and K. L. B. Brouwer. Use of a pharmacokinetic model incorporating discontinuous gastrointestinal absorption to examine the occurrence of double peaks in oral concentration-time profiles. Pharm. Res. 9:350-356 (1992).
16. Y. M. C. Wang and R. H. Reuning. A comparison of two surgical techniques for preparation of rats with chronic bile duct cannulae for the investigation of enterohepatic curculation. Lab. Animal Sci. 44:479-485 (1994).
17. M. A. Rudek, C. L. March, K. S. Bauer Jr., J. M. Pluda, and W. D. Figg. High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma. J. Pharmaceu. Biomed. Anal. 22:1003-1014 (2000).
18. V. Mummaneni, G. L. Amidon, and J. B. Dressman. Gastric pH influences the appearance of double peaks in the plasma concentration-time profiles of cimetidine after oral administration in dogs. Pharm. Res. 12:780-786 (1995).
19. S. L. Eeckhoudt, P. A. Evrard, and R. K. Verbeeck. Biliary excretion and enterohepatic cycling of r- and s-flurbiprofen in the rats. Drug Metab. Dispos. 25:428-430 (1997).
20. R. L. Smith. Factors affecting biliary excretion. In R. L. Smith (eds.), The Excretory Function of Bile, Chapman and Hall, London, 1973, pp 16-34.
21. S. K. Paulson, M. B. Vaughn, S. M. Jessen, Y. Lawal, C. J. Gresk, B. Yan, T. J. Maziasz, C. S. Cook, and A. Karim. Pharmacokinetics of celecoxib after oral administration in dogs and humans: Effect of food and site of absorption. J. Pharmacol. Exp. Thr. 297:638-645 (2001).
22. nd Ed., Marcel Dekker, New York, 1990, pp 23-90.
23. M. Gibaldi. Gastrointestinal absorption-physicochemical considerations. In M. Gibaldi (eds.) Biopharmaceutics and Clinical Pharmacokinetics, Lea & Febiger, Philadelphia, Pennsylvania, 1984, pp 49-57.
24. A. J. Jounela, P. J. Pentikainen, and A. Sothmann. Effect of particle size on the bioavailability of digoxin. Eur. J. Clin. Pharmacol. 8:365-370 (1995).
25. W. L. Chiou and S. Riegelman. Absorption characteristics of solid dispersed and micronized griseofulvin in man. J. Pharm. Sci. 60:1376-1380 (1971).
26. T. Nishihata, M. Ishizakd, and S. Yokohama. Effects of particle size of bulk drug and food on the bioavailability of U-78875. Drug Dev. Ind. Pharm. 19:2679-2698 (1993).
27. T. R. Bates, M. Gibaldi, and J. L. Kanig. Rate of dissolution of griseofulvin and hexoestrol in bile salt solutions. Nature 210:1331-1333 (1966).
28. K. Kakemi, H. Sezaki, R. Konishi, T. Kimura, and M. Murakami. Effect of bile salts on the gastrointestinal absorption of drugs. Chem. Pharm. Bull. 18:275-280 (1970).
29. D. Shinkuma, T. Hamaguchi, Y. Yamanaka, N. Mizuno, and N. Yata. Influence of bile on the gastrointestinal absorption of phenytoin in rats. Chem. Pharm. Bull. 33:5023-5027 (1985).
30. M. G. Traber, H. J. Kayden, and J. B. Green. Absorption of water-miscible forms of vitamin E in a patient with cholestasis and in thoracic duct-cannulated rats. Am. J. Clin. Nutr. 44:914-923 (1986).
31. A. Karim. Importance of food effect studies in early drug development. In K. K. Midha and T. Nagai (eds.), Bioavailability, Bioequivalence and Pharmacokinetic Studies, Business Center for Academic Societies, Japan, Tokyo, Japan, 1996, pp 221-229.
32. C. Tschanz, W. W. Stargel, and J. A. Thomas. Interactions between drugs and nutrients. Adv. Pharmacol. 35:1-26 (1996).
33. S. Pinsuwan, F. A. Alvarez-Nunez, S. E. Tabibi, and S. H. Yalkowsky. Spectrophotometric determination of acidity constants of 4-dedimethylamino sancycline (COL-3), a new antitumor drug. J. Pharm. Sci 88:535-537 (1999).
34. T. T. Kararli. Gastrointestianl absorption of drugs. Crit. Rev. Ther. Drug Carrier Syst. 6:39-85 (1989).
35. K. Takeuchi, O. Furukdawa, H. Tanake, and S. Okabe. Determination of acid-neutralizing capacity in rat duodenum. Influences of 16, 16-demethyl prostaglandin E2 and nonsteroidal antiinflamamatory drug. Dig. Dis. Sci. 31:631-637 (1986).
36. R. Weiner, W. Hartig, R. Haupt, and M. Gierth. Small intestine absorption in cancer patients - Basis for enteral feeding therapy in oncology. Z. Ernahrungswiss 23:157-170 (1984).